参考文献/References:
[1]Dymova MA, Kuligina EV, Richter VA. Molecular mechanisms of drug resistance in glioblastoma [J]. Int J Mol Sci, 2021, 22(12): 6385.
[2]Miglar A, Reuling IJ, Yap XZ, et al. Biomarkers of cellular aging during a controlled human malaria infection [J]. Sci Rep, 2021, 11(1): 18733.
[3]Mancini A, Xavier-Magalhes A, Woods WS, et al. Disruption of the β1L isoform of GABP reverses glioblastoma replicative immortality in a TERT promoter mutationdependent manner [J]. Cancer Cell, 2018, 34(3): 513-528.
[4]Geng J, Liu Y, Guo Y, et al. Correlation between TERT C228T and clinic-pathological features in pediatric papillary thyroid carcinoma [J]. Sci China Life Sci, 2019, 62(12):1563-1571.
[5]Ackermann A, apc A, Buchfelder M, et al. Chemicalhybridization of sulfasalazine and dihydroartemisinin promotes brain tumor cell death [J]. Sci Rep, 2021, 11(1):20766.
[6]Janovi T, Stojaspal M, Veverka P, et al. Human telomererepeat binding factor TRF1 replaces TRF2 bound to shelterin core hub TIN2 when TPP1 is absent [J]. J Mol Biol,2019, 431(17): 3289-3301.
[7]Dono A, Wang E, Lopez-Rivera V, et al. Molecular characteristics and clinical features of multifocal glioblastoma [J]. J Neurooncol, 2020, 148(2): 389-397.
[8]Bollam SR, Berens ME, Dhruv HD. When the ends arereally the beginnings: targeting telomerase for treatment of GBM [J]. Curr Neurol Neurosci Rep, 2018, 18(4): 15.
[9]刘千琪，尹晓雪，邹 艳，等. 弥漫浸润性胶质肿瘤中TERT和IDH突变联合分析的预后价值[J]. 中华病理学杂志，2018，47（9）：658-663.
[10]苏优勒，李 昊. ERT启动子突变、ATRX表达水平在人脑胶质瘤病人预后评估中的作用[J]. 中国临床神经外科杂志，2021，26（4）：246-249.
[11]赵宇航，王泽芬. 人脑胶质瘤IDH1突变状态与MGMT启动子甲基化、P53和TERT突变相关性[J]. 中国临床神经外科杂志，2018，23（5）：339-342.
[12]Hewer E, Phour J, Gutt-Will M, et al. TERT promoter mutation analysis to distinguish glioma from gliosis [J]. J Neuropathol Exp Neurol, 2020, 79(4): 430-436.
[13]Okla K, Wertel I, Wawruszak A, et al. Blood-based analysesof cancer: Circulating myeloid-derived suppressor cellsis a new era coming [J]. Crit Rev Clin Lab Sci, 2018, 55(6):376-407.
[14]Vengoji R, Ponnusamy MP, Rachagani S, et al. Novel therapies hijack the blood-brain barrier to eradicate glioblastomacancer stem cells [J]. Carcinogenesis, 2019, 40(1): 2-14.
[15]Cacciotti C, Choi J, Alexandrescu S, et al. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience [J]. J Neurooncol, 2020, 149(1): 113-122.
[16]BirayAvci C, Dogan F, Ozates Ay NP, et al. Effects of telomerase inhibitor on epigenetic chromatin modification enzymes in malignancies [J]. J Cell Biochem, 2018, 119(12):9817-9824.
[17]Wang JY, Wang WP. B7-H4, a promising target for immunotherapy [J]. Cell Immunol, 2020, 347: 104008.
[18]Yuan L, Ye J, Fan D. The B7-H4 gene induces immuneescape partly via upregulating the PD-1/Stat3 pathway in non-small cell lung cancer [J]. Hum Immunol, 2020, 81(5):254-261.
相似文献/References:
[1]谢宝树 张 林 王 宇 贾 锋 殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(03):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[2]宋贵东 综述 高之宪 审校.贝伐单抗治疗复发胶质母细胞瘤的研究进展[J].中国临床神经外科杂志,2015,(10):638.[doi:10.13798/j.issn.1009-153X.2015.10.022]
[3]李继强 杨吉安 邵灵敏 吴庭枫 刘宝辉 陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(03):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[4]桂志勇 冯 军 黄俊红 白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(03):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[5]王娇燕 孟凡华 刘魏然 魏春晓 林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(03):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[6]张治元 王汉东 樊友武 贾 玥 吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(03):69.
[7]赵宇航 王泽芬 徐成仕 李 凯 李志强.人脑胶质瘤IDH1突变状态与MGMT启动子甲基化、P53和TERT突变相关性[J].中国临床神经外科杂志,2018,(05):339.[doi:10.13798/j.issn.1009-153X.2018.05.011]
ZHAO Yu-hang,WANG Ze-fen,XU Cheng-shi,et al.Correlativity of IDH1 mutation with MGMT promoter methylation and P53 and TERT mutations in gliomas[J].,2018,(03):339.[doi:10.13798/j.issn.1009-153X.2018.05.011]
[8]郑锐哲 姜秀峰 陈二涛 孙兆良 冯东福.胶质母细胞瘤卒中术后继发硬膜下水瘤1例[J].中国临床神经外科杂志,2019,(02):128.[doi:10.13798/j.issn.1009-153X.2019.02.022]
[9]胡 玥,薛小燕,李子超,等.阿苯达唑抑制胶质瘤裸鼠模型肿瘤生长[J].中国临床神经外科杂志,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
HU Yue,XUE Xiao-yan,LI Zi-chao,et al.Albendazole inhibits tumor growth in nude mice model of glioma[J].,2019,(03):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
[10]殷安安 陆 南 贺亚龙 章 翔 刘玉河.TRIM38基因非CpG岛DNA甲基化与胶质母细胞瘤临床预后的关系[J].中国临床神经外科杂志,2020,(02):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
YIN An-an,LU Nan,HE Ya-long,et al.Impacts of TRIM38 non-CpG island DNA methylation alterations on clinical prognosis in patients with glioblastomas[J].,2020,(03):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]